TCM
DGX icon

Triumph Capital Management’s Quest Diagnostics DGX Stock Holding History

Triumph Capital Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.66K Hold
22
– – ﹤0.01% 1373
2026
Q1 		$4.31K Hold
22
– – ﹤0.01% 1352
2025
Q4 		$3.82K Buy
+22
New +$4.01K ﹤0.01% 1339

Other funds holding DGX

EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
AIM
Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
BCAM
Boston Common Asset Management Boston, Massachusetts $1.69B AUM 28.29% 1-Year Est. Return
JWM
JGP Wealth Management Bend, Oregon $1.11B AUM 35.22% 1-Year Est. Return
P
Paradiem Covington, Louisiana $464M AUM 45.56% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GIA
GHP Investment Advisors Denver, Colorado $2.72B AUM 27.58% 1-Year Est. Return

Triumph Capital Management's DGX Position: Q2 2026 in Review

Triumph Capital Management held its Quest Diagnostics (DGX) position steady in Q2 2026 at 22 shares worth $4.66K. The position accounts for ﹤0.01% of the portfolio, ranked #1373.

Triumph Capital Management first reported a position in DGX in Q4 2025 and has held it in 3 quarters since. 232 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Triumph Capital Management held 22 shares of Quest Diagnostics worth $4.66K as of Q2 2026.
  • Triumph Capital Management left its Quest Diagnostics share count unchanged in Q2 2026.
  • Quest Diagnostics made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1373 holding.
  • Triumph Capital Management first reported a position in Quest Diagnostics in Q4 2025 and has held it in 3 quarters since.
  • 232 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.